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Assessment and treatment of patients with underactive thyroid. 
Maggie Carson BN/RGN, MSc, Certificate in Adult Endocrine Nursing 
 
Aim 
The aim of this article is to assist nurses in their understanding of the management of 
patients with an underactive thyroid gland or hypothyroidism.  Hypothyroidism is one 
of the most common endocrine conditions.  It occurs when the thyroid gland does not 
produce enough of the hormone thyroxine (T4) causing many of the body’s functions to 
slow down.   
 
Intended learning outcomes: 
After reading this article you should be able to: 
1. Describe the structure and function of the thyroid gland and be able to give an 
example of a negative feedback mechanism. 
2. Identify the causes of hypothyroidism. 
3. Describe the main signs and symptoms associated with hypothyroidism. 
4. Describe how hypothyroidism is diagnosed and treated. 
5. Identify the need to provide patients with ongoing support and encouragement 
to adhere to treatment and to attend for annual check-ups. 
 
Introduction  
The thyroid gland secretes two hormones, triiodothyronine (T3) and thyroxine (T4).  
These hormones are iodinated molecules.  They have various effects on metabolism and 
protein synthesis and, together with human growth hormone and insulin, are necessary 
for growth and development in children.  Consequently, any under activity of the gland 
can result in widespread clinical manifestations.   Hypothyroidism is relatively 
common, affecting approximately 1 in 50 females and 1 in 300 males.  Patients on 
replacement therapy require long term management and follow-up to monitor their 
condition by an endocrinologist, their GP or both. 
 
Anatomy and physiology 
The thyroid is a small butterfly shaped gland located in the neck that sits in front of the 
larynx and is attached to the second and third tracheal cartilages. It consists of two 
lobes connected by an isthmus. Structures that lie in close proximity include the 
oesophagus, trachea, the parathyroid glands, the recurrent laryngeal nerves and the 
carotid arteries.   Enlargement of the thyroid (goitre) may compress the trachea and 
oesophagus.  Surgery of the thyroid may damage the parathyroid glands and the 
recurrent laryngeal nerves. 
The thyroid gland is highly vascular, receiving a rich blood supply (80-120mls of blood 
per minute) from the superior thyroid arteries, which branch from the external carotid 
arteries, and from the inferior thyroid arteries, which branch from the subclavian 
arteries.  Venous return is to the internal jugular veins via the thyroid veins.  (See 
Figure 1a – Tortora and Derrickson, 2006) 
The thyroid is one of the largest endocrine glands in the body weighing about 30g (1 
oz) and is the only endocrine gland that stores its own hormones in large quantities with 
enough thyroid hormones being stored for about 100 days supply (Tortora and 
Derrickson, 2006).  Each lobe is composed of cuboidal epithelium which forms a 
number of microscopic sac-like spheres called follicles.  Each follicle is surrounded by 
a basement membrane.  These follicles produce and store a thick sticky protein called 
colloid. Between the follicles are parafollicular cells (“C” cells), which secrete the 
hormone calcitonin; this together with parathormone from the parathyroid glands is 
involved in the metabolism of calcium (see Figure 1b – Tortora and Derrickson, 2006). 
The thyroid hormones, thyroxine or tetraiodothyronine (T4) so called because it 
contains four atoms of iodine and 15% of circulating tri-iodothyronine (T3) which 
contain three atoms of iodine are synthesized and secreted by the follicular cells as 
large precursor modules called thyroglobulin which is the major constituent of colloid.  
This synthesis of thyroid hormones is dependent on the availability of iodine in the diet, 
e.g. from table salt, seafood, milk and vegetables grown in iodine-rich soils.  Dietary 
iodine is absorbed from the small intestine, changed to iodide and transported in the 
blood to the thyroid gland, where it is taken up by the thyroid cells.  This process is 
called iodine trapping.  More T4 than T3 is produced, but T4 is converted in some 
tissues, mainly the liver and skeletal muscle, to the more biologically active T3 (85% of 
T3 is produced in this way).  Over 99% of all thyroid hormones are bound to plasma 
proteins during transport in the blood including thyroid-binding globulin (TBG).  Only 
the free unbound hormone is available for use by the tissues entering the cells and 
regulating the pituitary feedback mechanism.  If the levels of T4 and T3 in the blood 
fall, the hypothalamus releases thyrotrophin-releasing hormone (TRH), a tripeptide.  
The secretion of TRH is also stimulated by exercise, stress, malnutrition, low plasma 
glucose and sleep.  As the levels of TRH rise, the anterior pituitary gland is stimulated 
and secretes thyroid stimulating hormone (TSH), a polypeptide, which in turn 
stimulates the thyroid gland to produce and release more T4 and T3.  This is an 
example of negative feedback (see Figure 2 – Ross and Wilson).  
T4 and T3 secretion begins at the end of the twelfth week of life in utero.  It remains 
fairly constant throughout life increasing only during puberty and in women during 
their reproductive years especially when pregnant. 
The principal effect of thyroid hormones is to influence the metabolism of cells and, 
therefore, what is known as the basal metabolic rate (BMR).  Low levels of hormone 
are associated with a low body temperature (patients will complain of feeling cold), 
slow heart rate and weight gain whereas patients with high concentrations of thyroid 
hormones experience a rapid heart rate, heat intolerance and weight loss despite an 
increased appetite with high calorie intake.  
 
Hyposecretion of the thyroid hormones 
The cause of underactivity of the thyroid gland may be primary, resulting from disease 
of the thyroid, or secondary (“central”) due to pituitary or hypothalamic failure (see 
Table 1). 
 
Table 1: Causes of hypothyroidism 
Primary  Secondary  
Spontaneous atrophic (autoimmune 
destruction of the gland) 
Pituitary failure 
Goitrous (Hashimoto’s thyroiditis, drug 
induced, iodine deficiency, 
dyshormonogenesis) 
Hypothalamic failure 
Post ablative (following radioactive 
iodine) 
Post pituitary surgery 
Post thyroid surgery  
Transient  
Sub-clinical  
Congenital  
Aetiology 
Primary hypothyroidism accounts for 95% of all cases of hypothyroidism in adults 
(Walsh 1997).  It is six times more common in women than in men (Haslett et al 2002).  
It affects approx 1% of the adult population and is most common in elderly females. 
Of these, primary hypothyroidism as a result of autoimmune disease is the commonest 
cause of thyroid underactivity. It may be associated with other autoimmune diseases 
such as pernicious anaemia, vitiligo, Addison’s disease, hypoparathyroidism and 
insulin dependent diabetes mellitus (Lindsey and Toft 1997).  Hypothyroidism may 
also be iatrogenic, i.e. caused by previous treatment for thyrotoxicosis by means of 
surgery or radioactive iodine. 
Iodine deficiency is another cause of hypothyroidism (“endemic hypothyroidism”) and 
is due to insufficient dietary intake of iodine which in turn is usually due to low levels 
of iodine in the soil in the locality. This leads to reduced thyroid hormone production. 
Goitre is a frequent feature of this condition. This is due to the excess secretion of TSH, 
a proliferation of thyroid gland cells and enlargement of the gland.  Endemic 
hypothyroidism is rare in developed countries and where iodide supplementation is 
practiced but still occurs in areas where iodine levels in the water supply are low 
(usually inland areas which are far from the sea or in mountainous regions).  It is 
therefore still seen in the following areas; parts of central Africa, central Asia and 
central and Eastern Europe as well as in the Andes, the Himalayas and the Alpine areas 
of central Europe (Delange and Dunn 2005).  Interestingly, it is now also reappearing in 
developed countries such as New Zealand where the population has heeded public 
health advice about the dangers of too much salt in the diet and reduced their intake 
(Mann and Aitken, 2003). 
Some medication may also induce hypothyroidism.  For example, Lithium Carbonate 
(used to manage bipolar disorders) can result in goitrous hypothyroidism (Haslett et al 
2002), and Amioderone, an anti-arrythmic agent, may cause either transient or 
permanent hypothyroidism (Laurberg et al 2005). 
Congenital hypothyroidism occurs in approximately 1 in 3,500 live births and usually 
results from congenital absence of the thyroid gland; it can also be caused by certain 
genetic enzyme defects (dyshormonogenesis).  If congenital hypothyroidism is not 
detected and treated early, the child will not develop fully, either mentally or 
physically.  Neonatal screening for congenital hypothyroidism is performed in most 
developed countries at 5-7 days.  
 
Pathophysiology  
In primary hypothyroidism insufficient thyroxine is being produced by the thyroid 
gland.   Serum T4 is low and levels of TSH are high. The onset is slow and insidious 
and, because the affected individual is often an older person, it may be accepted as a 
normal part of ageing and it may therefore be some time before a medical opinion is 
sought.    Symptoms may include lethargy, depression, which can be severe, and an 
inability to ‘think quickly’.  The patient may report sensitivity to cold, weight gain and 
a general slowing down of body functions.   Peristalsis becomes markedly slower 
resulting in constipation which may be chronic and sometimes leads to faecal impaction 
or ileus (Greenspan, 2004).   
As a result of infiltration of the dermis, with mucopolysaccharide, non pitting oedema 
or myxoedema occurs which is most marked in the skin of the hands, feet and eyelids 
(Haslett et al, 2002).  The face may be puffy in appearance and is often either pale, due 
to a combination of vasoconstriction and anaemia, or may be yellowish in colour due to 
carotinaemia resulting from the reduced conversion of carotene to vitamin A and the 
consequent higher levels of carotene in the blood (Greenspan, 2004).  The hair may be 
sparse, coarse and brittle and often the outer portion of the eyebrows disappears (See 
Figure 3). 
Renal function is also affected; there is a decrease in the glomerular filtration rate and 
an impaired ability to excrete a water load.   
In women, hypothyroidism impairs the conversion of oestrogen precursors to 
oestrogens affecting Luteinising Hormone (LH) and Follicle Stimulating Hormone 
(FSH) production which in turn can lead to anovulatory cycles (menstrual cycles which 
vary in length and which have no ovulatory or leuteal phase).  The absence of ovulation 
results in infertility.  Hypothyroidism can also cause severe menorrhagia (abnormally 
heavy and prolonged regular menstrual bleeding) which may explain why many 
patients are also anaemic though this may also be due to impaired haemoglobin 
synthesis or impaired iron absorption in the gut (Greenspan, 2004). 
 
Medical Management 
 
Physical examination 
An assessment should first be made of the patient’s general appearance.  Changes that 
may indicate hypothyroidism include paleness, facial puffiness and a lack of facial 
expression.  Their skin and hair may appear dry and brittle and they may report they 
have noticed a change in texture.  Pulse and respiratory rate should be measured as in 
hypothyroidism these tend to slow down.  Blood pressure, however may be raised.  In 
patients with severe and prolonged hypothyroidism an ECG should be performed.  This 
may reveal sinus bradycardia with low voltage complexes and ST-T wave 
abnormalities (Haslett et al 2002).   A lipid profile should also be done as cholesterol 
levels may be raised. 
 
Diagnosis 
Thyroid function tests (TFTs) are used to diagnose both an underactive and overactive 
thyroid gland before treatment is initiated.  Diagnosis of hypothyroidism is confirmed 
by low plasma levels of T4 (usually < 5 pmol/L) and raised TSH levels (usually >20 
mU/L).   
Approximately 10 million TFTs are carried out in the UK each year at an estimated cost 
of £30 million (BTF News 2006).  This simple blood test measures levels of circulating 
TSH and free T4 (see Table 2).    T3 is not usually measured as it is not reliable enough 
to distinguish between euthyroid (normal thyroid function) and hypothyroid patients 
(Haslett et al, 2002). 
 
Table 2: Thyroid Function Tests 
Hormone Reference 
range 
Primary 
hypothyroidism 
Secondary  
hypothyroidism 
Sub-clinical  
hypothyroidism 
T4  < 5 pmol/L 
 
i.e. low 
Low Normal (usually lower end 
of normal reference range) 
Free T4 (measures 
unbound portion 
of T4 that is free 
10-27 
pmol/L 
   
to enter cells) 
T3  Low* Low or normal* Normal * 
TSH  >20 mU/L 
i.e. high 
Undetectable, 
normal or mildly 
elevated  
(5-20mU/L) 
Mildly elevated 
(5-20 mU/L) 
 
* T3 is not a sensitive indicator of hypothyroidism and should therefore not be 
measured. 
 
Nursing Assessment 
Assessment begins by taking a comprehensive history from the patient.  The 
 
commonest symptoms of hypothyroidism are tiredness and lethargy although there  
 
may be no symptoms or signs present.  Symptoms usually develop gradually and may  
 
be vague and general in nature slowly worsening  over months or years as the levels  
 
of thyroxine in the body fall. 
 
Knowledge of the clinical signs and symptoms of hypothyroidism (see Table 3) enable 
the nurse to formulate specific questions to identify specific health problems the patient 
may not have considered relevant and may fail to mention but which taken together 
help to confirm the diagnosis.   The patient should be asked about changes in their 
physical appearance, their activity and energy levels, sleep patterns, sensitivity to cold, 
muscle tone, body weight, loss of appetite, hair, skin tone, menstrual cycle and thought 
processes.  Questions specific to their usual daily routine and how organized they are 
may provide the nurse with clues as to subtle changes and how the patient is 
compensating.  With questioning the patient may, for example, recognize that they have 
become more forgetful but identify that they have compensated for this by writing 
themselves lists of things to do. 
Condition specific questionnaires have been designed and validated for use with 
patients with hypothyroidism: the Underactive Thyroid-Dependent Quality of Life 
Questionnaire (ThyDQoL) and the Underactive Thyroid Treatment Satisfaction 
Questionnaire (ThyTSQ).  The ThyDQoL has eighteen domains covering quality of life  
 
 
Table 3: Signs and symptoms of hypothyroidism (adapted from Kumer and Clark 1998 
and Haslett et al 2002) 
 
Cardiac/respiratory Bradycardia 
 Hypotension 
 Angina 
 Heart failure 
 Pericardial and pleural effusions 
 Coma 
Dematological Dry, course, flaky skin  
 Dry, brittle, unmanageable hair 
 Loss of eyebrows (especially outer third) 
 Myxoedema 
 Puffy eyes 
Gastrointestinal Constipation 
 Anorexia 
General Tiredness 
 Weight gain 
 Fluid retention 
 Cold intolerance/cold peripheries 
 Change in appearance 
 Goitre 
 Hoarse, deep voice 
Haematological Anaemia 
Neuromuscular Arthralgia 
 Myalgia 
 Carpal tunnel syndrome 
 Deafness 
Psychological Lethargy 
 Depression 
 Poor memory 
 Confusion 
 Psychosis/dementia 
Reproductive Poor libido 
 Impotence 
 Menorrhagia or oligomenorrhoea in 
women 
 Galactorrhoea 
 Infertility 
 
measures such as energy levels, physical capabilities, motivation, physical appearance 
and weight together with other aspects of life affected by hypothyroidism (McMillan et 
al 2004).  It is an individualized measure of the perceived impact of hypothyroidism on 
the patients’ quality of life and is a useful tool to use when assessing a new patient.   
It is important to remember that many symptoms are relatively non-specific and can be 
seen in patients without thyroid disease. With the advent of widely available and 
accurate thyroid function testing, relatively minor disturbances of thyroid function are 
frequently detected and are not always the cause of the patient’s symptoms. 
 
Management  
Current thyroid hormone replacement therapy as a treatment for hypothyroidism was 
established by beginning of the 1970’s (O’Reilly 2000).  Clinical guidelines 
recommend replacement therapy to relieve symptoms, restore euthyroid state and 
normalize serum TSH levels (Vanderpump et al 1996).  Uncomplicated cases of 
hypothyroidism are treated with replacement doses of Thyroxine (T4) which is 
available as 25, 50 and 100 mcg tablets.  Treatment should commence with a low dose 
of 25-50 mcg orally and increase by increments of 25-50mcg every 3-4 weeks until 
serum TSH is normal.   A typical dose would be 100-200 mcg/daily.  The half life of 
thyroxine is 6-7 days allowing for small dose adjustments to be made by adding or 
withdrawing a tablet once or twice weekly so the patient will not notice immediate 
relief of their symptoms.  Thyroxine is only partly absorbed after ingestion and food 
(especially those rich in calcium or iron), minerals, other drugs and tablet composition 
can all influence its absorption.  Tablets should be taken in the morning on an empty 
stomach and as a single daily dose.  Symptomatic relief should become apparent 2-4 
weeks after starting replacement therapy with improvements to puffy eyes and a 
reduction in weight often noticed in this time, but it will take 6-8 weeks for a steady 
state of thyroid hormones to be achieved (Elliot 2000). The patient and their family 
should therefore be advised that there will only be a gradual improvement in symptoms 
until this state is reached.  Until then, it is important to remind the patient’s family that 
symptoms of lethargy and mental slowness are part of the disease process.  
Improvement to hair and skin texture can take 3-6 months.  Patients should be 
encouraged to moisturize their skin if dry and flakey.  
Patients may need to wear extra clothing and bedding to help with cold intolerance and 
in some instances, prevent hypothermia.  In an attempt to reduce constipation patient 
should be advised to eat a high fibre diet. 
The patient and their family should also be advised that they will need to take thyroxine 
replacement for life.  This entitles the patient to free prescriptions including all other 
prescribed medication in addition to the thyroxine.  The majority of patients in the 
United Kingdom on thyroid replacement are taking a synthetic preparation containing 
Levothyroxine Sodium BP, Lactose, Maize Starch, Magnesium Sterate and sometimes 
Sucrose and/or powdered Acacia.  It is possible to get lactose free thyroxine for patients 
who are lactose intolerant.  Some UK clinicians are now prescribing T3 as well as T4 
for their patients.  These patients may be on synthetic T3 or T3/T4 combinations.  It is 
also possible to get natural thyroxine made from the thyroid glands of pigs but no 
advantages have been scientifically proven.  Side effects are rare and almost entirely 
related to either under-replacement (in which case the symptoms of hypothyroidism 
will not have been corrected) or over replacement producing symptoms of 
hyperthyroidism.  Adverse effects of over replacement include anxiety, restlessness, 
palpitations, angina, diarrhoea and vomiting, muscle wasting, osteoporosis (especially 
in post menopausal women) and atrial fibrillation (Clarke and Kabadi 2004).  The 
patient should also be informed about the signs and symptoms of over-replacement 
although this is uncommon.   
Once the level of serum TSH is within the normal reference range, the correct 
maintenance dose can be individualized on the basis of the patient’s symptoms and 
levels of TSH and T4.  The elderly usually require lower doses than young adults and 
may need their dose of thyroxine reduced.  
As thyroxine potentiates the effects of some other commonly prescribed medications 
(anticoagulants, amitriptyline, insulin, oral hypoglycaemics and tricyclic 
antidepressants) it is important to establish if the patient is on any of these and ensure 
the doses are adjusted accordingly.  In addition, the metabolism of thyroid hormones is 
accelerated by some drugs (barbiturates, carbamazipine, phenytoin, rifampicin) and the 
absorption of thyroxine is reduced by others (colestipol, colestyramine, calcium salts, 
cimetidine, iron) and so doses of T4 may need to be increased or decreased depending 
on the patients concomitant medication (BNF 2007). 
 
Nursing priorities and management: 
It is usual to treat patients with hypothyroidism on an ongoing basis in the community. 
The community nursing team should follow up medical treatment and explanations and 
ensure that patients understand the reasons for the thyroxine replacement therapy and 
the importance of attending for regular checks to monitor TFTs to ensure that a 
euthyroid state is both achieved and maintained.  Patients are seen in hospital for annual 
review in out-patient clinics which nowadays are often nurse-led.  Questionnaires such 
as the ThyTSQ mentioned earlier, a seven item measure of satisfaction with current 
treatment and a four item measure of satisfaction with past treatment (around the time 
of diagnosis) on a scale of 0 (very dissatisfied) to 6 (very satisfied) can be used by the 
nurse to assess patient satisfaction with their care.   Studies show that patients are least 
satisfied with their present understanding of their condition and the information 
provided at the time of their diagnosis (McMillan et al 2006).     
It is important that the patient is encouraged to comply with their treatment and to learn 
self management in regard to this and symptom control.  Despite this, studies suggest 
that 75% of patients remain overweight and 80% of patients report still feeling 
depressed even though their thyroid function tests are normal (O’Malley et al 2000).   
 
Specific problem groups and issues: 
 
 
Hypothyroidism and pre-existing Ischaemic Heart Disease 
 
Patients with a history of ischaemic heart disease should be started on a low dose of  
 
Thyroxine, 25mcg, which is gradually titrated every three to four weeks by 25mcg 
 
increments to the full replacement dose.  Care should be taken to ensure that these 
 
patients are not over replaced with T4 because of the risk of exacerbating further 
 
cardiac events.  Myocardial infarction and sudden death are recognized complications  
 
of increasing the metabolic rate in patients with a compromised coronary artery  
 
circulation.  Symptoms of angina may be exacerbated when thyroxine is first started.  
 
Approximately 40% of patients with angina cannot tolerate full replacement therapy 
 
despite the concomitant use of B-blockers  and vasodilators.  These patients may need  
 
to undergo successful coronary angioplasty or coronary artery bypass grafting before  
 
they are able to tolerate the full replacement dose (Walker and Toft, 2002).    
 
 
 
Hypothyroidism and pregnancy 
 During pregnancy there is an increase in the concentration of TBG resulting in a 
 
decrease in serum free T4 in patients with partial or complete thyroid failure.  This 
cannot be compensated for by increased secretion of  T3/T4 (Walker and Toft, 2002).   
 
If left untreated, pregnant women with primary hypothyroidism are at greater risk of  
 
developing pre-eclampsia, anaemia, going into premature labour and of having a  
 
stillbirth or a low birth weight baby (Lazarus and Othman 1991).   Pregnant women 
 
with known hypothyroidism should therefore have their dose of thyroxine increased  by 
 
25-50 mcg daily when conception is confirmed and their levels of serum TSH closely 
 
monitored each trimester to maintain a normal TSH (Kaplan 1992). 
 
 
 
Hypothyroidism and Myxodematous Coma 
 
In severe hypothyroidism, the patient may be admitted in a coma and perhaps be 
thought to be suffering from hypothermia. This represents a medical emergency in 
which intensive treatment and care are essential. It is characterised by a depressed level 
of consciousness, a severe fall in body temperature which may be as low as 25C and 
sometimes convulsions.  The pressure of cerebrospinal fluid (CSF) and its protein 
content are raised.  There is a 50% mortality rate (Strachan and Walker 2006).  
Treatment must begin immediately the diagnosis is suspected which is often before it 
can be confirmed biochemically.  The patient should be slowly rewarmed using a space 
blanket.    Intravenous T3 is given as a bolus every 8 hours until symptoms improve.   
The patient can then be switched to oral T4 at a starting dose of 50mcg/day. 
 
 
Hypothyroidism and ageing 
 
Some degree of hypothyroidism is common in older people with 5-20% of women and  
 
3-8% of men affected (Laurberg et al 2005).  Patients in their 70s and 80s who are 
 
already on replacement therapy may need a reduced dose of thyroxine from that 
 
which they were taking previously usually as a result of lower body weight and/or 
 
concomitant heart disease. 
 
 
 
Sub clinical hypothyroidism   
 
This is a term used to describe patients without the symptoms of hypothyroidism 
 
who are clinically euthryoid.  The diagnosis is entirely based on laboratory findings of  
 
an elevated serum TSH levels (>10mU/L) but normal free T4 levels (usually at the 
 
lower end of the reference range).  It is frequently observed in patients following 
 
surgery or Iodine 131 therapy for hyperthyroidism but also occurs spontaneously in 
 
over 5% of the female population due to sub-clinical auto-immune thyroid disease.  
 
These patients are seen as mildly hypothyroid and there is currently some debate as to 
 
whether or not they should be treated.  Patients with sub clinical hypothyroidism who 
 
also have the anti-thyroid peroxidase (TPO) antibodies have a greater risk of  
 
becoming overtly hypothyroid and treatment for these patients is recommended (Lock 
 
et al 2004).  Only some patients will feel better on replacement therapy (Cooper 2001): 
 
prevention may be better than cure but not all these patients will progress to have 
 
thyroid failure.    
 
 
 
Inappropriate thyroxine replacement 
 
Symptoms of hypothyroidism can be non-specific and include fatigue, low mood and  
 
weight gain.  A minority of individuals, looking for an explanation for and resolution 
 
from these symptoms may press their doctor for a trial of thyroxine replacement either 
 
as T4 alone or in combination with T3.  This may be initiated without biochemical 
 
confirmation of the diagnosis or despite their thyroid function tests being normal.  
 
Pollock et al (2001) have demonstrated that individuals with non-specific symptoms of  
 
hypothyroidism and normal T4 and TSH levels do not benefit from replacement  
 
therapy.   
 
In some patients , thyroxine replacement may be continued for years for what was in 
 
fact a short lived episode of thyroid failure.  In these individuals, thyroxine replacement 
 
should be stopped and TFTs checked 4-6 weeks later (Walker and Toft, 2002)  
 
 
 
Adherence to management regimens in hypothyroidism 
 
Patients are often poor at remembering to take long term medications routinely and 
 
poor adherence to thyroid replacement is not uncommon (McMillan et al 2006, Walsh 
 
2002). While the daily tablet regimen is not in itself complicated patients may not 
 
appreciate the need to titrate their dose to achieve a euthyroid state and prevent side 
 
effects and/or complications associated with hypo- or hyperthyroidism.  Other patients 
 
may feel despondent if the treatment does not make them feel as they did before the  
 
onset of their disease and consequently not adhere to their treatment  (Walsh 2002).  
 
Flynn et al (2005) demonstrate an association between being placed on a thyroid 
 
register and increased compliance with thyroid monitoring and improvement in  
 
biochemical control. In the UK the new General Medical Services contract financially 
 
rewards primary care practices for regularly measuring thyroid function tests in patients 
 
with hypothyroidism (Flynn et al 2005).  In some parts of the country disease specific 
 
automated registers prompt hypothyroid patients on replacement therapy to attend for  
 
blood tests (TSH levels) at 18-monthly intervals (Jung et al 1991). 
 
The findings of a raised serum TSH in a patient known to have been previously well 
 
controlled can indicate poor compliance but may also be due to the patient being on 
 
another medication which interferes with the absorption of T4 e.g. Ferrous Sulphate 
 
or with its metabolism e.g. anti-malarials.  The combination of a raised free T4 and 
 
raised serum TSH implies that a patient who is known to be poorly compliant with 
 
their treatment has taken excessive quantities of T4 for a few days prior to their 
 
appointment (Toft 1999).   
 
If compliance issues are suspected or there is doubt as to whether thyroxine  
 
is being absorbed patients can be asked to attend clinic and levels of T4 and TSH 
 
checked at hourly intervals for 8 hours  following the administration of oral thyroxine 
 
given by the nurse who observes the patient taking their tablet (s). 
 
Some patients notice a difference in symptoms if the brand of thyroxine they have 
 
been using is changed.  This can happen when their dose is altered as not all 
 
brands manufacture 25, 50 and 100 mcg tablets.  It can also happen because their 
 
local pharmacy switches to a different supplier. 
 
 
 
Annual review 
 
TFTs should be measured yearly in order to improve compliance and to ensure that  
 
the correct replacement dose is still being prescribed.  For this reason the patient  
 
should be asked if there have been any changes to their concomitant medications.  A  
 
full blood count and fasting serum lipids should also be measured. 
 
 
 
Conclusion 
 
There are currently over 500 000 people taking thyroid hormone therapy (Thyroxine) in 
the UK (Saravanan et al 2002)  In addition, there are 180,000 people with undiagnosed 
hypothyroidism and a suspected 3.6 million people with undiagnosed sub-clinical 
hypothyroidism.  Consequently it is vital that nurses working in both primary and 
secondary care settings are aware of the signs and symptoms of hypothyroidism and 
know how to monitor and support patients with this disease. 
 
 
Patient Support Groups 
 
 
British Thyroid Foundation     
 
www.btf-thyroid.org 
 
 
British Thyroid Association 
 
www.british-thyroid-association.org 
 
 
 
 
 
 
Time Out Activities 
 
 
Time Out 1 
 
Revise the normal anatomy and physiology of the thyroid gland.  Refamiliarise yourself 
with the principles of negative feedback mechanisms. 
 
Time Out 2 
 
What symptoms might a patient complain about that would prompt a GP to consider a 
diagnosis of hypothyroidism? Write a list of symptoms. 
 
Time Out 3 
Consider the consequences if a patient stopped taking their thyroid replacement therapy 
a) in the short term and b) long term? 
 
Time Out 4 
 
Using the internet find out what, if any, support is available to patients with 
hypothyroidism. Is there a national support group? Does it have local groups and is 
there one in your area? Could you go along to a meeting? 
 
Time Out 5 
 
Why is it important to monitor a patient’s thyroid levels while on replacement? What 
signs and symptoms are associated with excessive doses of replacement Thyroxine? 
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